Medical technology company Carl Zeiss Meditec AG ( CZMWF.PK) Thursday reported higher profit and revenue for the year, amid strong growth in all businesses.
Earnings before interest and tax rose 18.7 percent to 122.9 million euros with all regions and strategic business units contributing to growth. EBIT margin rose to 14.3 percent from 13.6 percent the previous year.
Revenue climbed 13.6 percent to 861.9 million euros, slightly exceeding the upper limit of the revenue forecast of 830 million euros to 860 million euros.
In the Ophthalmic Systems business, revenue advanced 8.7 percent to 345.97 million euros, driven by growing demand for innovative lasers for the refractive correction of vision defects.
Microsurgery revenues increased 17.8 percent to 321.16 million euros, amid particularly strong demand for surgical microscopes from the field of neuro/ENT surgery.
Surgical Ophthalmology business generated 91.67 million euros, an increase of 17.5 million euros from last year. The business benefited from demand for intraocular lenses for minimally invasive cataract surgery and the integration of a distribution acquisition in Spain.
Regionally, revenue climbed 14.2 percent in the Ameicas, 11 percent in the EMEA and 15.8 percent in the Asia/Pacific region.
During the year, Carl Zeiss Meditec invested 10.8 percent of its revenue in R&D.
The board proposed to the annual general meeting a dividend of 0.40 euros per share for financial year 2011/2012.
Looking ahead, the company said its objective remains to grow at least as fast as the industry in the markets and regions in which it operates. The firm said it is well on its way to achieving its EBIT margin target of 15 percent by 2015.
The stock fell 0.58 percent to close at 22.11 euros on Wednesday.
For comments and feedback: editorial@rttnews.com